Clear Search sequence regions


  • binds protein (1)
  • biogenesis (3)
  • c myc (2)
  • cellular (1)
  • cholesterol (2)
  • factors (5)
  • gene (2)
  • humans (1)
  • K ras (6)
  • kras protein, human (1)
  • mice (2)
  • mice nude (1)
  • organelle (1)
  • oxygen (3)
  • p21 ras (2)
  • PGC 1α (2)
  • ppargc1a protein, human (1)
  • protein human (3)
  • receptor 1 (2)
  • regulates (1)
  • signal (1)
  • Sp1 (6)
  • species (3)
  • SQLE (7)
  • TFAP2E (3)
  • xenografts (1)
  • Sizes of these terms reflect their relevance to your search.

    It is well known that activation of oncogenic K-ras alone is insufficient to drive tumor development and that additional factors are needed for full malignant transformation, but the metabolic pathways and regulatory mechanisms that facilitate K-ras-driven cancer development remain to be characterized. Here we show that SQLE, a key enzyme in cholesterol synthesis, is upregulated in K-ras-driven cancer and its high expression is correlated with poor clinical outcome. K-ras regulates SQLE expression in a biphasic manner through reactive oxygen species and MYC signaling. Surprisingly, the pro-oncogenic role of SQLE is not mediated by promoting cholesterol synthesis, but by metabolic removal of squalene and thus mitigating its suppressive effect on the PGC-1α-mediated mitochondrial biogenesis and metabolism. Genetic silencing of SQLE in pancreatic cancer cells causes an accumulation of cellular squalene, which binds to Sp1 protein and causes a formation of a tight Sp1-TFAP2E promoter DNA complex with a highly negative binding score. This aberrant squalene/Sp1/TFAP2E promoter complex hinders the expression of TFAP2E and its downstream molecule PGC-1α, leading to suppression of mitochondrial metabolism and an almost complete inhibition of tumor formation in vivo. Importantly, administration of pharmacological squalene to mice bearing pancreatic cancer xenografts could significantly inhibit tumor growth. Our study has revealed a previously unrecognized role of SQLE in regulating gene expression and mitochondrial metabolism to facilitate K-ras-driven cancer development, and identified SQLE as a novel therapeutic target for potential treatment of pancreatic cancer. Copyright © 2025 Elsevier B.V. All rights reserved.

    Citation

    Junchen Pan, Rui Liu, Wenhua Lu, Hongyu Peng, Jing Yang, Qianrui Zhang, Tiantian Yu, Bitao Huo, Xiaoying Wei, Haixi Liang, Lin Zhou, Yameng Sun, Yumin Hu, Shijun Wen, Jie Fu, Paul J Chiao, Xiaojun Xia, Jinyun Liu, Peng Huang. SQLE-catalyzed squalene metabolism promotes mitochondrial biogenesis and tumor development in K-ras-driven cancer. Cancer letters. 2025 Apr 28;616:217586

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 40015662

    View Full Text